Actualités

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV) just got a lot easier to answer. The company posted $15.002 billion in Q1 2026 revenue, beating consensus by $284 million, and management raised full-year adjusted EPS guidance to $14.08 to $14.28. With the stock yielding nearly 3%, the question is whether the ... This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie

AbbVie (NYSE:ABBV) has quietly become one of healthcare’s most underrated growth stories. CEO Robert A. Michael told investors after Q1, “We are off to an excellent start in 2026, with first-quarter results exceeding our expectations.” The numbers back him up. Immunology revenue hit $7.29 billion, with Skyrizi up 30.9% and Rinvoq up 23.3%. Yet shares ... AbbVie Stock Will Hit $300 on This Date

Based on the average brokerage recommendation (ABR), AbbVie (ABBV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.

Most Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) owners assume they are buying broad market diversification. The latest Schwab fact sheet tells a different story. SCHD’s top 10 holdings now account for 41% of the fund’s $71.6 billion in net assets, well above the roughly 30% top-10 weight typical of large-cap dividend peers. SCHD still earns ... SCHD Now Concentrates 42 Percent of Your Money in Just 10 Stocks. Here Is Who Should Still Own It

Two retirees walk into retirement with the same amount of money. One builds a portfolio that pays $120,000 a year but barely grows. The other settles for $65,000 a year and focuses on dividend growth. At first glance, the first retiree appears to have won. Twenty-five years later, the second retiree may have collected more ... The Retiree Who Chose $65,000 Instead of $120,000 and Ended Up Richer

In the last week, the United States market has stayed flat, yet it has seen a significant increase of 24% over the past year with earnings forecasted to grow by 19% annually. In this context, identifying stocks that are estimated to be undervalued can offer investors potential opportunities for capitalizing on price discrepancies relative to their fair value.

The iShares Core Dividend Growth ETF (NYSEARCA:DGRO) was built for investors who want a paycheck that gets bigger every year, not a yield chase. DGRO tracks the Morningstar US Dividend Growth Index, screening for companies with at least five consecutive years of dividend growth and payout ratios under 75%. The fund pays a roughly 2.2% ... 64 Years of Raises: How DGRO Finds Companies That Never Cut Dividends

PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.

Over the last 7 days, the United States market has remained flat, yet it is up 24% over the past year with earnings anticipated to grow by 19% annually in the coming years. In this context of robust growth expectations, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential long-term gains.

Now's the time to load up on these high-yielders.

If you are wondering whether AbbVie at around US$227.73 is still offering fair value, the starting point is to understand what the current price actually reflects. The stock has inched up 0.2% over the past week and 9.2% over the last month, while the year to date return is slightly down 0.7% and the 1 year, 3 year and 5 year returns sit at 23.1%, 82.9% and 142.8% respectively. These moves have kept AbbVie on the radar as investors weigh long term performance against current pricing. Recent...

Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is down around 1% year to date even after a 6% one-month bounce. That stagnation has left a handful of high-margin operators trading at forward multiples that look out of ... 3 Ridiculously Cheap Healthcare Stocks to Buy in June

Paying $2,000 a month in rent is often described as throwing money away. Homeownership, by contrast, is treated as the only reliable path to wealth. Yet under the right conditions, a dividend portfolio large enough to cover your rent can leave you with greater flexibility and, in some cases, a larger net worth than owning ... Why a Dividend Portfolio That Pays Your Rent May Beat Homeownership by $500,000 Over 20 Years

AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.

While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.

Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.

Over the last 7 days, the United States market has dropped 2.4%, yet it remains up by 22% over the past year, with earnings forecasted to grow by 18% annually. In this context, identifying undervalued stocks can be particularly appealing as they may offer significant potential for appreciation when their intrinsic value is recognized by the market.

Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.

Over the last 7 days, the United States market has dropped 2.4%, though it has risen by 22% over the past year, with earnings forecasted to grow by 18% annually. In this context, identifying stocks that might be trading below their estimated intrinsic value can present potential opportunities for investors looking to capitalize on undervalued assets.

If you own JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI), you bought it for a reason that still holds. JEPI pays monthly. It leans on a defensive equity sleeve and runs a covered call overlay that turns volatility into income. It is the largest active ETF in the country, yielding near 8.2%. But a younger competitor now runs the same ... Forget JEPI, Goldman’s S&P Income ETF Has Beaten It by 42 Points Since Launch

New cancer therapies may help fund dividend growth.

AbbVie (NYSE:ABBV) at $224.95 sits at the center of a sharp bull-bear debate. The pharma giant has climbed 53.59% since the start of 2024 off its 2024 lows, but a balance sheet carrying negative shareholders’ equity of -$6.6 billion complicates conviction at this price. AbbVie is the immunology heavyweight behind Skyrizi, Rinvoq, and legacy Humira, ... Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225

Before the stock surged, management was laying out a multi-billion-dollar growth story that directly contradicted consensus estimates, if you knew where to look.

Is ABBV a good stock to buy? We came across a bullish thesis on AbbVie Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $225.42 as of June 9th. ABBV’s trailing and forward P/E were 110.50 and 15.82 respectively according to Yahoo Finance. AbbVie […]

Over the last 7 days, the United States market has experienced a 4.1% drop, yet it remains up by 21% over the past year with anticipated earnings growth of 18% per annum in the coming years. In this fluctuating environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.

ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.

Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.

Over the last 7 days, the United States market has experienced a 4.1% drop, although it remains up by 21% over the past year with earnings forecasted to grow by 18% annually. In such fluctuating conditions, identifying stocks that might be undervalued based on current market estimates can present opportunities for investors seeking potential growth at a reasonable price.